Screener / SEC EDGAR /CIK 0001607678 /10-K filed Feb 11, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Viking Therapeutics, Inc. VKTX

Compare with peers Embed
SEC comment letters, last 20 years

5 reviews of VKTX's filings by SEC staff

UPLOAD and CORRESP
Reviews 5 latest letter Mar 31, 2025
Questions asked 50 each answered in the company's own letter
No closing letter 4 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 8 UPLOAD
  2. 2. Questions in them 50 numbered comments
  3. 3. Company replies 13 CORRESP
  4. 4. Reviews closed 1 of 5 closing letter

Half the closed reviews took 21 days or less from the first letter to the closing letter.

Form 10-K

2025-03-31 to 2025-04-21 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2025-04-21
Results discussion (MD&A)
Operations · Research and Development Expenses, page 65
SEC asked (1)
We note from the disclosures on page 5 that you have four programs in various stages of development. Please provide disclosures to be included in future filings that disclose the costs incurred during each period presented for each of your key research and development programs separately.
Rest of the question

If you do not track your research and development costs by program, revise to disclose that fact and explain why you do not maintain and evaluate research and development costs by program. For amounts that are not tracked by program, provide a break down by nature or type of research and development expenses incurred which should reconcile to total research and development expense on the Statements of Operations.

VKTX answered
The Company respectfully advises the Staff that it does not track its research and development costs by program but rather only by external and internal development costs, because it manages its research and development efforts dynamically, taking into account large unmet medical need, scientific data, probability of technical and regulatory success and other considerations. The Company will include in its future filings disclosures consistent with the foregoing.
Rest of the answer

In addition, the Company respectfully advises the Staff that it will provide in its future filings a break down by nature or type of research and development expenses incurred (specifically, internal development costs and external development costs) which will reconcile to total research and development expense on the Statements of Operations.

Read in the reply
In its next report

First report after the company's reply of Apr 8, 2025: 10-Q filed Apr 24, 2025 ↗, against the 10-Q filed Oct 23, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

General and Administrative Expenses, page 66
SEC asked (2)
We note your discussion of the changes in general and administrative expenses cites multiple factors without any quantification of the individual factors. Please provide disclosures to be included in future filings to quantify the impact of each material contributing factor and explain the reasons driving these changes. Refer to Item 303 (a) to (c) of Regulation S-K for guidance.
VKTX answered
The Company respectfully advises the Staff that, as required by Item 303(a) to (c) of Regulation S-K, it will include in its discussion of changes in research and development expenses and general and administrative expenses in future filings disclosures that quantify the impact of each material contributing factor and explain the reasons driving the changes.
Read in the reply
In its next report

First report after the company's reply of Apr 8, 2025: 10-Q filed Apr 24, 2025 ↗, against the 10-Q filed Oct 23, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2025-04-21

Form S-3

2016-07-14 to 2016-07-15 · 2 questions · 1 letter from the SEC, 1 from the company
No closing letter
General
SEC asked (1)
Please be advised that we will not be in a position to accelerate the effective date of this registration statement until we resolve any issues concerning your pending confidential treatment request.
VKTX answered
The Company acknowledges the Staff's comment and will await processing of the Company's confidential treatment request.
Read in the reply
Plan of Distribution, page S-11
SEC asked (2)
Your disclosure of the plan of distribution of the securities covered by the prospectus supplement included in this registration statement states that sales may be made: …by any method permitted by law deemed to be an “at-the-market” equity offering as defined in Rule 415 promulgated under the Securities Act, including sales made directly on or through the Nasdaq Capital Market, the existing trading market for our
Rest of the question

common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Please tell us whether sales made to or through a market maker or sales made in privatelynegotiated transactions satisfy the “at the market offering” definition under Rule 415. If any sales method does not constitute a sales method that is deemed to be an “at the market offering” as defined in Rule 415 or if any material information with respect to a particular offering has been omitted, please confirm that you will file an additional prospectus supplement at the time of such sales or tell us why such additional filing would not be necessary.

VKTX answered
The Company acknowledges the Staff’s comment and confirms that sales made to or through a market maker or sales made in privately-negotiated transactions do not satisfy the “at the market offering” definition under Rule 415. The Company further confirms that, if any sale method employed by the Company does not constitute a sales method that is deemed to be an “at the market offering” as defined in Rule 415, or if any material information with respect to a particular offering has been omitted from the prospectus supplement included in the Registration Statement, the Company will file an
Rest of the answer

additional prospectus supplement at the time of such sale.

Read in the reply

Form S-1

2015-12-09 to 2016-04-06 · 1 question · 1 letter from the SEC, 8 from the company
No closing letter
General
SEC asked
Please identify the lead underwriter(s) on the prospectus cover page. Please note that we may defer further review of any amendment to your registration statement that does not include the name(s) of the lead underwriter(s).
VKTX answered
The Company advises the Staff that Maxim Group LLC will be acting as the lead underwriter for the

Company’s proposed offering. In response to the Staff’s comment, the Company has revised the prospectus cover page and other applicable sections of the Registration Statement to identify Maxim Group LLC as the lead underwriter, as well as to identify FBR Capital Markets & Co. as an additional underwriter, for the Company’s proposed offering.

Paul Hastings

LLP | 1117 S. California Avenue | Palo Alto, California 94304 t:
Read in the reply

Also in this review: company letter, Mar 25, 2016, company letter, Mar 31, 2016, company letter, Apr 1, 2016, company letter, Apr 1, 2016, company letter, Apr 4, 2016, company letter, Apr 6, 2016, company letter, Apr 6, 2016

Form S-1

2015-03-27 to 2015-03-27 · 10 questions · 1 letter from the SEC, 0 from the company
No closing letter
SEC letter of Mar 27, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Our Product Pipeline, page 4
SEC asked (1)
We note that you have not yet identified product candidates for your EPOR and DGSAT1 programs focusing on anemia and obesity dyslipidemia, respectively. In light of the early stage of development with respect to these products, please remove them from the pipeline table here and at page 82 of the prospectus.
VKTX answered

No reply letter found.

Prospectus Summary · Our Product Pipeline, page 4
SEC asked (2)
We note that your pipeline table includes a column with the heading “future development, licensing opportunities.” Please revise your disclosure with respect to your pipeline to specify which product candidates this statement applies to and how development of these products differs from the other candidates you identify.
VKTX answered

No reply letter found.

Prospectus Summary · Our Product Pipeline, page 4
SEC asked (3)
Please revise your pipeline table to indicate that when you plan to commence Phase 2A trials of VK2809 for Dyslipidemia and NASH. In this regard, we note your disclosure on page 1 that pending sufficient funding, you plan to initiate a Phase 2 trial of VK2809 in hypercholesterolemia in 2015.
VKTX answered

No reply letter found.

Prospectus Summary · Our Product Pipeline, page 4
SEC asked (4)
Please also revise your pipeline table to indicate that initiation of Phase 2B or drug-drug interaction studies for VK0612 are contingent upon your receipt of additional funding.
VKTX answered

No reply letter found.

Use of Proceeds, page 55
SEC asked (5)
Please revise your use of proceeds discussion to separately allocate the proceeds you intend to use for the development of VK0612, your EPOR program for anemia and the DGAt-1 inhibitor program. Please also indicate how far the proceeds from the offering will you to proceed with respect to the continued development of VK0612.
VKTX answered

No reply letter found.

Business, page 80
SEC asked (6)
Please revise your disclosure to indicate when the clinical trials for your product candidates occurred.
VKTX answered

No reply letter found.

Business, page 80
SEC asked (7)
Please expand your disclosure in the appropriate part of your Business section to describe the material terms of your collaboration with the Academic Medical Center at the University of Amsterdam with respect to VK2809 and VK0214 including the parties’ rights and obligations, duration of the agreement, termination provisions and any payment provisions.
VKTX answered

No reply letter found.

Business, page 80
SEC asked (8)
Please confirm that the research services agreement filed as Exhibit 10.29 reflects your collaboration with Academic Medical Center at the University of Amsterdam. In this respect, we note that the research services agreement includes reference to “statements of work” which outline the rights and obligations of the parties to the agreement and certain payment terms.
Rest of the question

However, these statements of work do not appear to have been filed with the research services agreement or otherwise filed as an exhibit to the registration statement. Accordingly, please file any such statements of work describing your collaboration with the University of Amsterdam.

VKTX answered

No reply letter found.

VK5211: A Selective Androgen Receptor Modulator (SARM) for Hip Fracture, page 83
SEC asked (9)
We note your disclosure that the initial Phase 1 clinical trial for VK5211 reflected statistically significant increases in lean muscle mass. Please disclosure the p-value and what p-value in this context indicates about the statistical significance of your results.
VKTX answered

No reply letter found.

Principal Stockholders, page 146
SEC asked (10)
Please update your principal stockholder table so that it is as of the most recent practicable date.
VKTX answered

No reply letter found.

Form S-1

2014-06-18 to 2014-09-19 · 35 questions · 4 letters from the SEC, 3 from the company
No closing letter
Risk factorsDebtDerivatives and hedgingResults discussion (MD&A)Critical estimates
General
SEC asked (1)
We note that there are a number of additional exhibits that still need to be filed. Please provide these exhibits as promptly as possible. Please note that we may have comments on these materials once they are provided.
VKTX answered
The Company has filed with the Registration Statement all of the exhibits other than Exhibits 1.1 and

5.1. The Company advises the Staff that Exhibits 1.1 and 5.1 are still being finalized and will be filed with a subsequent amendment to the Registration Statement. The Company acknowledges the Staff’s note that the Staff may have comments on any materials filed as an exhibit to the Registration Statement, and will endeavor to file the remaining exhibits with a subsequent amendment to the Registration Statement as promptly as possible following finalization of the documents.

The Company
Rest of the answer

advises the Staff that pursuant to a letter submitted to the Commission under separate cover on the date hereof, the Company is requesting confidential treatment of certain provisions contained in Exhibits 10.12, 10.13 and 10.21 filed with the Registration Statement.

Read in the reply
General
SEC asked (2)
Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to their use for our review.
VKTX answered
The Company hereby confirms that the graphics included in the Registration

Statement are the only graphics the Company will use in its prospectus.
Read in the reply
General
SEC asked (3)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
Rest of the question

Similarly, please supplementally provide us with any research reports about you that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act of 1933 added by Section 105(a) of the Jumpstart Our Business Startups Act by any broker or dealer that is participating or will participate in your offering.

VKTX answered
to the Staff’s comment, the Company is supplementally providing to the Staff under separate cover written communications that were presented to potential investors in reliance on Section 5(d) of the Securities Act. The Company advises the Staff that potential investors have not been permitted to retain copies of such written communications and that the written communications were not sent electronically to potential investors.
Rest of the answer

In the event the Company uses additional materials in reliance on Section 5(d) of the Securities Act, the Company will supplementally provide the Staff with copies of such materials as promptly as possible.

The Company also advises the Staff that, based upon information received by the

Company from the underwriters identified in the Registration Statement, no research reports about the Company have been published or distributed in reliance on Section 2(a)(3) of the Securities Act by any broker or dealer that is a participant in the offering. The Company will supplementally provide to the Staff research reports, if any, that are published or distributed in reliance upon Section 2(a)(3) of the Securities Act or Section 105(a) of the JOBS Act if the Company becomes aware that any reports are published or distributed.

Read in the reply
Prospectus Summary, page 1
SEC asked (4)
Where the following terms first appear in the Prospectus Summary, please give the meaning and significance of such terms in plain language that may be understood by a lay reader not acquainted with the relevant industry or scientific field:  selective androgen receptor modulator;  metformin;  renally-impaired;  clinically significant, and  statistically significant.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages 2, 72 and 74 of the Registration Statement to include disclosure regarding the meaning and significance of the terms “selective androgen receptor modulator”, “metformin”,

“renally-impaired”, “clinically significant” and “statistically significant”, in each case in the first instance where the term is used in the Registration Statement.
Read in the reply
The Company · VK0612 for Type 2 Diabetes, page 1
SEC asked (5)
We note your disclosure in the third bullet point in this section, which states that VK0612 has been well-tolerated at and above doses that you plan to administer in your Phase 2b clinical trial. Please expand your disclosure to disclose the doses that you plan to administer in your Phase 2b clinical trial.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages 2, 71 and 83 of the Registration Statement to include the doses that the Company plans to administer in its Phase 2b clinical trial for VK0612.
Read in the reply
The Company · VK0612 for Type 2 Diabetes, page 1
SEC asked (6)
Please describe the purpose of your end-of-Phase 2 meeting with the FDA and how such meeting impacts your planned regulatory development of VK0612.
VKTX answered
to the Staff’s comment, the Company has described the purpose of the end-of-Phase 2 meeting with the FDA and how such meeting impacts the Company’s planned regulatory development of VK0612 on page 72 of the Registration Statement, the first instance where the end-of-Phase 2 meeting is mentioned in the Registration Statement.
Read in the reply
Risks Related to Our Business, page 4
SEC asked (7)
Please revise your risk factor discussion in this section to note that you have received an opinion from your independent registered public accounting firm that expresses substantial doubt about your ability to continue as a going concern.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page

5 of the Registration Statement to include a reference to the going concern risk.
Read in the reply
Agreements with Ligand, page 5
SEC asked (8)
We note your disclosure at page 90 that pursuant to the Master License Agreement, you will issue common stock having an aggregate value of $29 million to Ligand at the closing of your initial public offering. Please revise your disclosure to include this information in each location in which you make reference to the upfront fee payable to Ligand in equity under the terms of the Master License Agreement.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages 5, 73 and 136 of the Registration Statement to include disclosure to the effect that the upfront fee payable to Ligand in equity has a value of $29.0 million and will be issued at the closing of the Company’s initial public offering.
Read in the reply
Risk Factors
SEC asked (9)
We note your disclosure on page F-15 which states that as of December 31, 2013 you had federal and state net operating loss carryforwards of approximately $158,000 and $158,000, respectively. Please add an appropriately titled risk factor discussing your ability to use your net operating loss carryforwards.
Rest of the question

In doing so, please quantify the amount of your net operating loss carryforwards in the risk factor, disclose when they will begin to expire and describe any annual limitations on the use of the carryforwards.

VKTX answered
to the Staff’s comment, the

Company has added a risk factor on page 44 of the Registration Statement regarding the use, quantity, expiration and limitations of its net operating loss carryforwards.
Read in the reply
Risks Related to Our Business · Our drug candidates may cause undesirable side effect…, page 15
SEC asked (10)
Please identify the party responsible for the drug development program of the small molecule inhibitor CD-917.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages 15, 81 and 82 of the Registration Statement to note that Sankyo Company, Ltd., now Daiichi Sankyo Company, Ltd., was responsible for funding and conducting the clinical development program for CS-917.
Read in the reply
Our employment agreements with our executive officers may require us…, page 30
SEC asked (11)
Please identify the executive officers with employment agreements containing change in control and severance provisions in this risk factor.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 30 of the Registration Statement to clarify that the employment agreements with each of the Company’s executive officers contain change in control and severance provisions.
Read in the reply
Risks Related to Our Intellectual Property · If we fail to comply with our obligations in the agreements under which…, page 31
SEC asked (12)
Please expand your risk factor disclosure to summarize the various circumstances in which Ligand may be permitted to terminate the Master License Agreement.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 31 of the Registration Statement to include a summary of the circumstances in which Ligand may be permitted to terminate the Master License Agreement.
Read in the reply
Changes in U.S. patent law could diminish the value of patents in general,…, page 35
SEC asked (13)
Please identify and describe the recently enacted patent reform legislation and legislation currently being implemented which you reference in your risk factor discussion. In this regard, please discuss any impact such legislation will have your patent rights.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 36 of the Registration Statement to more fully discuss recently enacted patent reform legislation, legislation currently being implemented and the potential impact of such legislation on the Company’s patent rights.
Read in the reply
We may not be able to protect our intellectual property rights throughout the…, page 36
SEC asked (14)
We note your statements that the legal systems of certain countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and that the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S.
Rest of the question

Please disclose which countries you are referencing and whether you have any licensed patents or patent application pending in such countries.

VKTX answered
The Company acknowledges the Staff’s comment and has revised the disclosure on pages

36 and 37 of the Registration Statement to disclose the countries the Company is referencing, as well as the Company’s licensed patents and patent applications pending in such countries.
Read in the reply
Use of Proceeds, page 49
SEC asked (15)
We note your statement that you cannot predict the stage of development you expect to achieve in clinical trials and preclinical trials for your product candidates using proceeds from the offering. While we understand the inherent uncertainty with respect to the development of product candidates, where you have identified specific purposes for which you intend to use the offering proceeds, investors are entitled to
Rest of the question

your best estimate as to how far such proceeds will allow you to proceed towards the achievement of the specified purposes. As such, please revise your disclosure to provide an estimate as to how far in the planned clinical trials of VK0612 and VK5211, and the development of your three preclinical drug candidates the offering proceeds will enable you to reach. You may, as necessary, provide additional disclosure that advises investors of the particular factors and assumptions that form the basis of your estimate, any uncertainty surrounding your estimate and the reasons that the actual results could vary.

VKTX answered
to the

Staff’s comment, the Company has revised the disclosure on page 49 of the Registration Statement to note the stage of development the Company expects to reach with each of its drug candidates using the estimated net proceeds from the offering.
Read in the reply
Critical Accounting Policies · Convertible Notes Payable and Related Debt Conversion Feature Liability, page 61
SEC asked (16)
Please expand your disclosure to provide the amount of interest payable on the convertible notes as of March 31, 2014.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 62 of the Registration Statement to disclose the amount of accrued interest payable on the convertible notes as of March 31, 2014.
Read in the reply
Common Stock Fair Value, page 62
SEC asked (17)
We may have additional comments on your accounting for stock compensation or any beneficial conversion features once you have disclosed an estimated offering price. Please supplementally provide us with a quantitative and qualitative analysis explaining the difference between the estimated offering price and the fair value of each equity issuance through the date of effectiveness for the preceding twelve months.
VKTX answered
The Company acknowledges the Staff’s comment and notes that the Company has disclosed under “Management’s Discussion and

Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation” on page 63 of the Registration Statement all of its stock issuances since the Company’s inception on

September 26, 2012.
Rest of the answer

The Company will supplement this disclosure in the event it issues additional stock-based compensation prior to the date of effectiveness.

The Company’s board of directors had determined at the time that each share of the

Company’s common stock issued on September 26, 2012, April 15, 2013, July 15, 2013 and February 20, 2014 had a deemed fair value of $0.01 per share. In connection with the preparation of the financial statements necessary for inclusion in the Registration Statement, in 2014 the Company reassessed the estimated fair value of its common stock at each of these dates using a retrospective valuation performed by a third party valuation specialist prepared in accordance with methodologies outlined in the AICPA Practice Aid Valuation of Privately-Held-Company Equity Securities Issued as Compensation. For each of the September 26, 2012, April 15, 2013 and July 15, 2013 issuances, the Company concluded that its common stock issued on those dates had fair values less than or equal to the $0.01 per share of common stock estimated fair value on the date of issuance. For the February 20, 2014 issuance, the Company concluded that the reassessed fair value had a higher price per share of common stock than the original estimated fair market value of $0.01 per share. The vesting of the February 20, 2014 stock issuance is based solely on two performance criteria, rather than time. As of March 31, 2014, it was deemed not probable that either of the two performance criteria would be met; therefore, no stock-based compensation expense was recorded through March 31, 2014 for the February 20, 2014 award. When and if the performance criteria are deemed probable, the Company will record stock-based compensation expense using the higher reassessed fair value to record stock compensation over the remaining estimated period for which the performance criteria are expected to be achieved.

The Company first commenced preliminary discussions with investment bankers and its legal counsel about the possibility of preparing for an initial public offering in late March 2014, subsequent to the Company’s last stock issuance. Moreover, through May 20, 2014, three months after the date of the Company’s last stock issuance, the Company had virtually no assets, very limited operations, only two employees and nominal value. On May 21, 2014, the Company signed a Master License Agreement with Ligand Pharmaceuticals Incorporated to acquire the rights to develop two clinical stage assets and three pre-clinical stage assets. The Company believes the deemed fair market value for the Company’s common stock increased upon the execution of the Master License Agreement. However, the Company believes there is no correlation between the deemed fair value of the Company’s common stock at February 20, 2014, the last date for which stock was issued by the Company (or at any date prior to February 20, 2014), and the valuation of the

Company upon and following the Company’s entry into the Ligand Master Licensing Agreement on May 21, 2014. Therefore, the Company does not expect that a determination of the estimated offering price will have any impact on the

Company’s stock-based compensation analysis for previously granted awards.

Read in the reply
Business
SEC asked (18)
Please disclose, where applicable in your business section, when investigational new drug applications (“INDs”) were filed for the commencement of clinical trials for VK0612 and VK5211, the name of the trial sponsor and the subject of the INDs. If an IND was not filed pertaining to any of your clinical trials, please explain why an IND was not required.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages 74 and 85 of the Registration Statement to include disclosure regarding the INDs filed for each of VK0612 and VK5211.
Read in the reply
VK0612: A Fructose-1,6-bisphosphatase (FBPase) Inhibitor for Type 2 Diabetes, page 73 · Diabetes and the Market, page 73
SEC asked (19)
We note your disclosure that it is estimated that over half of all patients treated for type 2 diabetes fail to achieve ADA-recommended target blood glucose levels. Please disclose the ADA-recommended target blood glucose levels.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 75 of the

Registration Statement to include the ADA-recommended target blood glucose levels.
Read in the reply
Current Type 2 Diabetes Therapies and Unmet Need, page 76 · Phase 2a Proof-of-Concept Trial, page 79
SEC asked (20)
We note that the discussion of your clinical trial makes reference to p-values. Please explain what the term “p-value” refers to and what it indicates about the statistical significance of results obtained from the trial.
VKTX answered
The Company respectfully advises the Staff that the term “p-value” refers to the probability of obtaining the observed result under a hypothesis that assumes no difference between treatment groups. Statisticians refer to this hypothesis as the null hypothesis. If a difference is observed, then the p-value is the probability that the observed difference could have occurred, assuming the null hypothesis is true. The term statistical significance generally refers to results where the p-value is less than or equal to 0.05.
Rest of the answer

In such cases, the probability that the observed result could have occurred, assuming the null hypothesis to be true, is interpreted to be less than or equal to 5%. The Company has revised the tables on pages 80 and 81 of the Registration Statement in response to the Staff’s comment.

Read in the reply
Phase 1b Clinical Trial in Patients with Poorly-Controlled Type 2 Diabetes, page 79
SEC asked (21)
Please revise your table on page 80 to explain what the abbreviations “SD” and “CI” refer to in the context of your clinical results for the Phase 1b clinical trial.
VKTX answered
The Company has revised the tables on pages 80 and 81 of the Registration Statement to explain the abbreviations “SD” and

“CI”.
Read in the reply
VK5211: A Selective Androgen Receptor Modulator (SARM) for Muscle Wasting · Clinical Date for VK5211, page 85
SEC asked (22)
We note your disclosure that there were no reported clinically significant drugrelated adverse events and no clinically significant changes in liver function tests, prostate-specific antigen, hematocrit or electrocardiogram readings. Please revise your disclosure to clarify whether any subjects in your trials experienced serious adverse events determined to be related to treatment.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 87 of the Registration Statement to clarify that there were no serious adverse events determined to be related to treatment.
Read in the reply
VK5211: A Selective Androgen Receptor Modulator (SARM) for Muscle Wasting · Clinical Date for VK5211, page 85
SEC asked (23)
Please expand your disclosure for the first Phase 1 clinical trial to provide the primary and secondary endpoints, and compare them to the actual results observed.
VKTX answered
The Company has revised the disclosure on page 87 of the Registration Statement to provide the primary and secondary endpoints of the first

Phase 1 clinical trial, and to compare them to the actual results observed.
Read in the reply
VK5211: A Selective Androgen Receptor Modulator (SARM) for Muscle Wasting · Clinical Date for VK5211, page 85
SEC asked (24)
We note your discussion of the results of the second Phase 1 clinical trial for VK5211. Please expand your disclosure to provide the primary and secondary endpoints of the clinical trial.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 87 of the Registration Statement to provide the primary and secondary endpoints of the second Phase 1 clinical trial.
Read in the reply
VK5211: A Selective Androgen Receptor Modulator (SARM) for Muscle Wasting · Clinical Date for VK5211, page 85
SEC asked (25)
We note that in the second phase 1 clinical trial, VK5211 demonstrated statistically significant increases in lean body mass with a positive trend in strength and performance measurements. In addition to the accompanying table, please expand your narrative disclosure of the trial to quantify and describe the statistically significant increases in lean body mass.
VKTX answered
The Company has revised the disclosure on page 87 of the Registration Statement in response to the Staff’s comment.
Read in the reply
Agreements with Ligand · Management Rights Letter, page 93
SEC asked (26)
Please revise your disclosure to identify the “certain contractual management rights” that you granted to Ligand under the Management Rights Letter as discussed on page 93.
VKTX answered
to the Staff’s comment, the Company has revised the disclosure on page 95 of the Registration Statement to identify the contractual management rights granted to Ligand under the Management Rights Letter.
Read in the reply
Lock-Up Agreements, page 129
SEC asked (27)
Please confirm that the lock-up agreement will be filed as part of the underwriting agreement. If not, please file the form of lock-up agreement as an exhibit. Notes to Financial Statements 7. Subsequent Events, page F-18
VKTX answered
The Company hereby confirms that the form of lock-up agreement will be filed as Exhibit A to the form of underwriting agreement that will be filed as Exhibit 1.1 via an amendment to the Registration Statement.

Notes to Financial Statements

7. Subsequent Events, page F-18
Read in the reply
Lock-Up Agreements, page 129
SEC asked (28)
Please expand your disclosure of the master license agreement to discuss the consideration to be paid, the rights and obligations of each party, and all significant terms of the agreement. If you intend to respond to these comments with an amended draft registration statement, please submit it and any associated correspondence in accordance with the guidance we provide in the Division’s October 11, 2012 announcement
Rest of the question

on the SEC website at http://www.sec.gov/divisions/corpfin/cfannouncements/drsfilingprocedures101512.htm. Please keep in mind that we may publicly post filing review correspondence in accordance with our December 1, 2011 policy (http://www.sec.gov/divisions/corpfin/cfannouncements/edgarcorrespondence.htm). If you intend to use Rule 83 (17 CFR 200.83) to request confidential treatment of information in the correspondence you submit on EDGAR, please properly mark that information in each of your confidential submissions to us so we do not repeat or refer to that information in our comment letters to you.

VKTX answered
to the Staff’s comment, the Company has revised the disclosure on pages F-17, F-18 and F-19 of the

Registration Statement to include additional information about the Master License Agreement, including the consideration to be paid, the rights and obligations of each party and all other significant terms of the Master License Agreement.
Read in the reply
SEC letter of Sep 15, 2014 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Notes to Financial Statements
SEC asked (4)
Accrued License Fees and License Fees Expense, page F-17 1. Please disclose the settlement terms that would require the license fees to be settled in common stock upon the IPO. In addition, please provide us a thorough analysis regarding the basis for your accounting treatment for recording the accrued license fee at fair value at each period.
Rest of the question

Specifically state if you believe the liability is a derivative and provide the applicable accounting literature you relied upon.

VKTX answered

No reply letter found.

Notes to Financial Statements
SEC asked (5)
Convertible Notes Payable, page F-18 2. Please tell us your basis for recording the embedded conversion feature in the Ligand note at fair value. Tell us what consideration was given to ASC 470-20-35-1.
VKTX answered

No reply letter found.

Notes to Financial Statements
SEC asked (6)
Stockholders’ Equity, page F-20 3. You state your employees agreed to lower salaries in exchange for receiving stock upon the IPO. You state you have not recorded a liability for the stock to be issued because you do not believe the IPO was probable at June 30, 2014. Please tell us why stock compensation was not recorded with an entry to donated capital in stockholders’ equity.
VKTX answered

No reply letter found.

Notes to Financial Statements
SEC asked
Subsequent Events (Unaudited), page F-24 1. Please revise to disclose the date through which subsequent events have been evaluated and whether that date is the date the financial statements were issued or were available to be issued. Refer to ASC 855-10-50-1.
VKTX answered

No numbered answer found in the reply. Read the reply ↗

Prospectus Summary · Summary Financial Data, page 9
SEC asked (1)
Refer to your response to comment 1. Please tell us the settlement terms that resulted in an increase to the pro forma license fees and interest expense on September 6, 2014. Please tell us how you calculated this additional pro forma expense.
Rest of the question

In doing so, please tell us the pre-money valuation before and after the repurchase of 1,862,203 shares and, to the extent repurchase of these shares does not fully explain the change in the premoney valuations, explain additional factors that contributed to the change in the values. Notes to Financial Statements 4. Accrued License Fees and License Fees Expense, page F-17

VKTX answered
The Company respectfully advises the Staff that the Master License Agreement was amended on September 6, 2014 to increase the number of shares of common stock of the Company (the “Common Stock”) issuable to Ligand thereunder (the

“Amendment”, and the Master License Agreement, as amended by the Amendment is referred to herein as the “Amended Master

U.S. Securities and Exchange Commission

Page

License Agreement”).
Rest of the answer

Prior to the Amendment, pursuant to the Master License Agreement, Ligand was entitled to receive a certain number of shares of Common Stock upon the closing of a financing transaction based on two factors: (i) the deemed value of the Company prior to the completion of the financing transaction (including an IPO); and (ii) the number of shares of Common Stock deemed outstanding prior to the completion of the financing transaction. Prior to the Amendment, the number of shares of Common Stock deemed to be outstanding under the Master License Agreement included only those shares actually outstanding prior to the financing transaction.

Pursuant to the Amendment, the parties agreed that the shares of Common Stock deemed to be outstanding prior to the financing transaction would include the shares actually outstanding prior to the financing transaction (as set forth in the initial

Master License Agreement), plus the shares issuable to Ligand pursuant to the Master License Agreement, plus the shares issuable to a consultant to the Company upon the closing of the financing transaction, plus the shares issuable upon the closing of the financing transaction to holders of certain outstanding promissory notes issued by the Company. As a result of amending the Master License Agreement to increase the number of shares of Common Stock deemed outstanding prior to the financing transaction, Ligand will be entitled to receive additional shares of Common Stock upon completion of the financing transaction. Pursuant to the Amendment, the Company and Ligand also agreed to change one of the percentages referenced in Schedule 6 from 55% to 50%, but this change had an immaterial impact on the number of shares of Common Stock issuable to Ligand under the Amended Master License Agreement.

The Amendment did not reflect a change in the estimated valuation of the Company. Both prior to and following the Amendment, the estimated value of the Company is based on $11.00 per share, the midpoint of the price range set forth in the Registration Statement, and the same aggregate number of shares of Common Stock deemed outstanding prior to the IPO. In order to accommodate the additional 1,820,779 shares issuable to Ligand under the Amended Master License Agreement, based on an estimated IPO price of $11.00 per share, but maintain the Company’s valuation, the Company agreed to repurchase shares from the

Company’s current stockholders. The number of shares of Common Stock subject to repurchase by the Company is 1,862,203, which is the sum of (i) the additional 1,820,779 shares of Common Stock issuable to Ligand under the Amended Master

License Agreement, plus (ii) 4,062 shares of Common Stock issuable to a consultant to the Company upon the closing of the IPO, plus (iii) 39,959 shares of Common Stock issuable upon the closing of the IPO to the holders of certain outstanding promissory notes issued by the Company, based on an estimated IPO price of $11.00 per share, the midpoint of the price range set forth in the Registration Statement. Accordingly, the number of shares of Common Stock subject to repurchase by the Company is approximately the exact number of additional shares of Common Stock issuable to Ligand pursuant to the Amended Master License Agreement.

The Company respectfully advises the Staff that the $20,028,569 additional pro forma expenses resulting from the Amendment is the product of

(i) 1,820,779, the number of additional shares of Common Stock issuable to Ligand under the Amended Master License Agreement, multiplied by (ii) $11.00, the midpoint of the price range set forth in the Registration Statement.

Notes to Financial Statements

4. Accrued License Fees and License Fees Expense, page F-17

Read in the reply
Prospectus Summary · Summary Financial Data, page 9
SEC asked (2)
Refer to your response to comment 1. Please tell us how you considered the adjustment feature based on the deemed value of the Company prior to the IPO to value the license consideration and why the monetary value of your obligation is fixed at inception. We note you state in the response that the amount is to be classified as a derivative liability until that share amount becomes known.
Rest of the question

If you determine that this obligation should not be accounted under ASC 480, please provide us with a detailed analysis of the appropriate accounting. Your response should include references to the specific sections of the accounting literature to support the accounting and how you analyzed each scope criterion. 5. Convertible Notes Payable, page F-18

VKTX answered
The Company respectfully advises the Staff that in accordance with Accounting Standards Codification (“ASC”) Topic 480-10-25-14(a), Certain Obligations to Issue a Variable Number of Shares, a financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability, if, at inception, the monetary value of the obligation is based solely or predominately on a fixed monetary amount known at
Rest of the answer

inception. Furthermore, the example set forth in ASC Topic 480-10-55-22, Obligation to Issue Shares with Monetary Value Based on a Fixed

Monetary Amount Known at Inception, provides that sometimes the monetary value of the obligation to issue shares is not entirely fixed at inception, and is based, in part, on variations in the fair value of the issuer’s equity shares. The example further provides that although the monetary amount of the obligation at settlement may differ from the initial monetary value because it is tied to the change in fair value of the issuer’s equity shares, the monetary value of the obligation is predominately based on a fixed monetary amount known at inception. ASC Topic 480-10-55-22 provides that this type of obligation should be accounted for and classified as a liability in accordance with ASC Topic 480-10-25-14(a) as noted above, and measured subsequently at fair value with changes in fair value recognized through earnings in accordance with ASC Topic 480-10-35-5.

In regards to the Master License Agreement, the Company respectfully advises the Staff that the monetary amount payable to Ligand is fixed based on the deemed valuation of the Company prior to the IPO. The number of shares to be issued to Ligand in settlement of the obligation will vary based on the value of the Company’s per share equity at the time of the IPO. Therefore, in accordance with ASC Topic 480-10-55-22, the Company conducted an assessment of the deemed valuation of the Company as of May 21, 2014, the date the Company entered into the Master License Agreement, and, based on that valuation, determined the fixed monetary amount to be paid to Ligand. Consistent with the example provided in ASC Topic 480-10-55-22, the monetary value to be paid at settlement (the IPO) may differ from the initial monetary value (the value of the license determined on

May 21, 2014) because it is based on the value of the Company’s equity at the time of the IPO; however, the monetary value is predominately based on a fixed monetary amount known at inception. The Company respectfully advises the Staff that subsequent valuations of the Company have not been materially different than the initial valuation performed on May 21, 2014. Therefore, the Company believes that the monetary value of the obligation is predominately based on a fixed monetary amount known at inception, and a variable number of shares will be issued to Ligand based on the value of the Company’s per share equity at the time of the IPO and, accordingly, the Company has appropriately classified the license consideration as a liability in accordance with ASC Topic 480-10-25-14(a) at inception and subsequently recognized the change in the fair value of the liability through earnings.

The Company also acknowledges that in the prior response letter to the Staff, the Company inadvertently referred to the liability as a derivative liability. As discussed above, the Company indeed followed the accounting under ASC Topic 480 and did not deem the Master License Agreement as a derivative instrument under ASC Topic 815, Derivatives and Hedging.

5. Convertible Notes Payable, page F-18

Read in the reply
Prospectus Summary · Summary Financial Data, page 9
SEC asked (3)
Refer to your response to comment 2. Your disclosure on page F-19 appears to indicate that Ligand note is only convertible upon the occurrence of certain events. It appears the notes were not convertible at issuance or any time prior to a qualified private financing or your initial public offering.
Rest of the question

If the notes were not convertible, please tell us how you analyzed the fact that the conversion feature appears to give Ligand the option to convert or receive cash upon subsequent financing and why this conversion option is a derivative.

VKTX answered
advises the Staff that the Ligand Note is convertible upon the earlier to occur of a qualified private financing or the Company’s initial public offering. As of June 30, 2014, the Company had determined the occurrence of a qualified private financing, as defined under the Ligand Note, not to be probable on a standalone basis.
Rest of the answer

In addition, as of June 30, 2014, the Company had determined the closing of an initial public offering not to be probable on a standalone basis.

However, as of such date, the Company determined that it was probable that one of the two transactions – either a qualified private financing or an initial public offering – would occur. Accordingly, the Company determined as of

June 30, 2014 that the Ligand Note would be converted into shares of Common Stock or cash pursuant to its terms.

As set forth in the

Company’s prior response letter to the Staff, the amount payable upon exercise of the conversion feature under the Ligand Note provides for a substantial premium upon redemption and is not based on changes in an observable market or an observable index. Accordingly, the conversion feature embedded in the Ligand Note is not deemed to be “clearly and closely related” to the Ligand Note. In addition, although the Company determined as of June 30, 2014 that the Ligand

Note would be converted pursuant to its terms, Ligand still maintained the option to determine whether the obligation would be converted into shares of Common Stock or cash. As a result, in accordance with ASC Topic 815-15 and ASC Topic 470-20-15-4, the embedded conversion feature contained in the Ligand Note is required to be bifurcated from the Ligand Note, recorded as a derivative liability and marked to market in each reporting period.

The Company respectfully advises the Staff that although the Company believes the foregoing treatment of the Ligand Note is appropriate, in the event the Company had elected to account for the Ligand Note in accordance with ASC Topic 470-20-35-1, net loss for the three and six-month periods ended June 30, 2014 would decrease by approximately $50,000 with a corresponding decrease in total liabilities and an increase in total stockholders’ equity (deficit) at June 30, 2014, which the Company deems immaterial.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
19 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 41 letters filed since 2014-06-19. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VKTX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.